News & Views
Collaboration extends Development Programme targets
Oct 06 2020 Read 1135 Times
An expansion to its existing multi-target collaboration agreement with LG Chem, the life sciences division of the South Korean LG Group, will see Avacta’s Affimer XT™ serum half-life extension system incorporated into a new programme of biotherapeutics development that could potentially bring milestone payments of up to $55m to Avacta Group.
The extension of the partnership, original established in December 2018, includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer-term clinical development milestones totalling $98.5m for two therapeutics to be developed using the Affimer XT technology. LG Chem also has the exclusive rights to develop and commercialise these new products on a world-wide basis.
Avacta Group chief executive Dr Alastair Smith said: “I am delighted with this expansion to the agreement with LG Chem, with whom we have developed a strong collaborative partnership. LG Chem is a world-class drug development partner with excellent biologics manufacturing and clinical development capabilities and a pioneering vision to develop innovative therapies.”
Avacta Group was referenced in the following research papers
In This Edition Articles - Expanding the Boundaries of Light Scattering for Macromolecules - Electrostatic Charges and Their Effects on Weighing - How the world’s most advanced analytical...
View all digital editions
Feb 28 2021 Virtual event
Mar 03 2021 Guanghzou, China
Mar 08 2021 Virtual Event
Mar 22 2021 Digital event
Apr 14 2021 Tokyo, Japan